Variety of THC and CBD oils addresses demand
for alternative cannabis consumption options
TORONTO,
Jan. 26, 2016 /CNW/ - Mettrum
Health Corp. ("Mettrum" or the "Company") (TSXV:MT), a
fully-integrated licensed producer (LP) of premium cannabis
products, launched its much-anticipated line of Mettrum Cannabis
Oils today.
Mettrum Cannabis Oils will be priced at
$90 for one 40 ml bottle, which
contains the equivalent medicinal content of five grams of dried
marijuana. Mettrum produces whole-flower cannabis extracts using
state-of-the art supercritical fluid CO2 extraction technology. The
process extracts the major cannabinoids (THC and CBD), as well as
the minor cannabinoids, terpenes and flavonoids that contribute to
the overall medicinal value of medical cannabis. The result of this
process is a highly concentrated resin. This extract is then
suspended in an oil to make it easier to administer orally.
Mettrum uses medium chain triglyceride oil (MCT) in our
formulations. MCT is naturally occurring and used widely in
the food, pharmaceutical and natural products industry. It is
highly stable, flavourless, odourless, and allows for increased
absorption making it ideal to use in cannabis oils.
"As Canada's
second LP to receive a license to sell cannabis extracts, we've
been working hard to deliver accessibly priced, premium oils for
our clients," said Michael Haines,
CEO of Mettrum. "We are responding to the demand from patients and
health care professionals alike for alternative consumption methods
of medical cannabis."
Today, Mettrum is launching three oils in the
Red, Blue, and Yellow categories, in line with the Mettrum
Spectrum™, a trademarked system that helps physicians and their
patients select the cannabis strain or strains that are most
appropriate for their particular medical need. The Mettrum
Spectrum™ allows for the categorization of medical cannabis
products based on different ratios of key medicinal cannabinoids:
cannabidiol (CBD) and tetrahydrocannabinol (THC). The Blue and
Yellow category oils are notably unique as they are derived from
rare strains of cannabis with a high ratio of CBD to THC ̶
making them a relevant treatment for an expanded population
of prospective patients. In the coming weeks, additional products
will be added to broaden the selection across the categories that
make up the Mettrum Spectrum™.
The launch comes on the heels of the announcement
that Mettrum received a license from Health Canada for the
production of cannabis at its new 60,000-square-foot production
facility in Bowmanville,
Ontario.
"The new facility gives us the production capacity to fulfill
clients' needs in a fast-growing sector, while still producing the
premium products that they have come to expect from us," said
Haines. "We're pleased to be able to provide our clients with
consistent supply of our full range of products at all times."
About Mettrum Cannabis Oils
Mettrum
produces cannabis oils with different ratios of the major
cannabinoids (THC and CBD) to meet client's unique medical needs.
The Mettrum Spectrum™ categorization of cannabis simplifies the
choice of oil by creating parity between the composition of dried
marijuana and the related oil.
About the Mettrum Spectrum™
The
Mettrum Spectrum™ is designed to simplify the dialogue around
medical cannabis by categorizing Mettrum strains according to THC
and CBD levels, using a straightforward, colour-coded system. The
adoption of the Mettrum Spectrum™, allows health care practitioners
to recommend strains to their patients with confidence.
About Mettrum Health Corp
Mettrum Health Corp. is a Tier-1 Industry Issuer listed on TSX
Venture Exchange. Mettrum Ltd., a wholly owned subsidiary, is a
Toronto-based company and licensed
producer of medical cannabis under the Marihuana for
Medical Purposes Regulations (Canada) issued pursuant to
the Controlled Drugs and Substances
Act (Canada)
(MMPR). The Company is a leading producer and vendor of medical
cannabis under the MMPR system and has three licensed production
facilities totalling 85,000 square feet representing annual
production capacity of approximately 12,000 kilograms.
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION: This news release includes certain "forward-looking
statements" under applicable Canadian securities legislation.
Forward-looking statements are necessarily based upon a number of
estimates and assumptions that, while considered reasonable, are
subject to known and unknown risks, uncertainties, and other
factors which may cause the actual results and future events to
differ materially from those expressed or implied by such
forward-looking statements. Such factors include, but are not
limited to: general business, economic, competitive, political and
social uncertainties; delay or failure to receive board,
shareholder or regulatory approvals; and the results of operations.
There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements. The Company and Mettrum disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law.
Neither the Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
Exchange) accepts responsibility for the adequacy or accuracy of
this Press release.
SOURCE Mettrum Health Corp.